MULTIPLE MYELOMA

In an interview with Targeted Oncology, Dan T. Vogl, MD, MSCE, discussed a phase 1 study which evaluated modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.

Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.

The importance of patient education, remote monitoring, and infection prophylaxis in the safe administration of bispecific antibody therapy for relapsed/refractory multiple myeloma.

David M. Dingli, MD, PhD, discusses the advantages and considerations of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory multiple myeloma, helping patients make informed treatment decisions.

Expert perspective on teclistamab, a bispecific antibody, in the context of multiple myeloma treatment, discussing its potential benefits and associated considerations.

An exploration of the landscape of immunologic therapies and alternative approaches for relapsed/refractory multiple myeloma, including bispecific antibodies, XPO1 inhibitors, venetoclax, and more.

David M. Dingli, MD, PhD, a hematologist at Mayo Clinic, as he discusses a challenging case of pentarefractory multiple myeloma in a 76-year-old patient and explores novel treatment options.

Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.

While there was no significant difference in overall survival between the daratumumab and control groups, safety profile results and follow-up data support daratumumab’s continued evaluation in relapsed/refractory multiple myeloma.

In the first article of a 2-part series, Sikander Ailawadhi, MD, looks at how the field has changed for treatment of patients with relapsed/refractory multiple myeloma and how recent study results with teclistamab show the impact of targeting BCMA in these patients.

Researchers used split-dose busulfan, fludarabine, and post-transplant cyclophosphamide on 6 patients in a phase 2 study, and further research is warranted.

The improvement in progression-free survival in the venetoclax arm of the study was not statistically significant compared to the control arm but results still trend positively.

Positive response and preliminary evidence of longer progression-free survival was observed with a venetoclax-based triplet therapy vs a doublet, in a phase. 2 study.

The observed benefits of ciltacabtagene autoleucel in patients with multiple myeloma and poor prognostic features are consistent with the overall the population of CARTITUDE-4.

In the phase 3 CARTITUDE-4 trial, ciltacabtagene autoleucel was shown to be effective when used in patients with multiple myeloma exhibiting poor prognostic features.

At separate live virtual events, Brea C. Lipe, MD, and Amandeep Godara, MD, MBBS, discussed options for the same elderly patient with multiple myeloma who is not able to receive a transplant.

Researchers identified KDM6A’s role in CD38 regulation and found that an EZH2 inhibitor could potentially reduce resistance to an anti-CD38 antibody in multiple myeloma cells.

Although response rates were lower among patients given previous anti-BCMA therapy, teclistamab shows promise for all patients with relapsed/refractory multiple myeloma.

At a median duration of response of 12.2 months, the objective response rates with forimtamig across all dose levels was 66.7% with a very good partial response rate of 54.2%, according to data from a phase 1a dose-escalation trial.

According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.

The Dara-KRd regimen with double transplant induced deep response rates and a high minimal residual disease negativity rates among patients with high-risk, newly diagnosed multiple myeloma.

Madhav V. Dhodapkar, MBBS, discusses some of the immunotherapies under investigation and those that are being highlighted at the 20th International Myeloma Society Annual Meeting for patients with multiple myeloma.

Findings presented at IMS 2023 suggest multi-specific strategies will be needed to avoid the antigen loss created by sequential mono-immunotherapies.

Dr Ajai Chari highlights the advantages of approved bispecific therapies as off-the-shelf options for patients with rapidly progressing multiple myeloma, highlighting the necessity for Phase 3 studies to confirm long-term benefits and safety. In closing, Dr Chari emphasizes the role of healthcare teams in managing side effects and complications, supporting the utility of bispecifics through unprecedented remissions and improved quality of life for patients.

Findings from a systematic review on the efficacy of bispecific antibodies were presented during the 20th International Myeloma Society Annual Meeting.

Ajai Chari, MD, discusses managing toxicities in patients with relapsed/refractory multiple myeloma treated with emerging bispecific therapies, emphasizing common adverse events including cytokine release syndrome, target-related toxicities such as neutropenia, and mitigation strategies such as pre-medication, early intervention with tocilizumab, and dose modulation.

Dr Ajai Chari highlights the CARTITUDE-1 study for its impressive results in the treatment of patients with relapsed/refractory multiple myeloma, noting a high response rate after three-year updates, which led to the accelerated approval of cilta-cel therapy.

Ajai Chari, MD, details the accelerated FDA approval of talquetamab based on data from the MonumenTAL-1 study showing positive response rates in patients with advanced multiple myeloma. The study highlighted the latest efficacy results of every-two-week dosing, which demonstrated an advantageous option for patients treated with four or more lines of therapy and triple class exposure.